Skip to main content

Search Results

Announcing a New Light The Night T-shirt Contest Winner, Drumroll Please…

The Leukemia & Lymphoma Society (LLS) has officially tallied up the votes for the 2016 Light The Night t-shirt contest submissions, and the winning design comes from 37-year-old Joshua Redmond of Centerville, Ohio.

A graduate of Ohio University’s School of Fine Art, Redmond earned his degree in graphic design and printmaking and has been working professionally in the industry for over a decade.

Leukemia

FDA Approves New Maintenance Treatment for AML

Some promising news to kick off Blood Cancer Awareness Month – on September 1, 2020, the U.S. Food and Drug Administration approved a new oral maintenance treatment for certain adult patients with acute myeloid leukemia (AML).

CC-486 (Onureg®) is now approved for the continued treatment of adult patients with AML who achieved first complete remission (CR) or CR with incomplete blood count recovery (Cri) following intensive induction chemotherapy and who are not able to undergo intensive curative therapy, such as hematopoietic stem cell transplant.

Progress on AML but More Work to Do

A Q&A with Amy Burd, PhD, LLS Vice President of Research Strategy

Today is AML World Awareness Day, a day to acknowledge the struggle to tackle one of the most challenging blood cancers, while shining a light on advances in the prevention, management and treatment of acute myeloid leukemia (AML).

Born with leukemia, Eevie beats the odds and turns four!

After Eevie was born, she was diagnosed with a rare form of childhood blood cancer that affects 1 in 5 million newborns. She was given a 17 percent chance of surviving to age 2. This month, Eevie celebrated her fourth birthday. Each year her mother, Brynne, has shared her progress on this blog (you can read those stories here).

The last year has been incredible. The first word that comes to mind is “freedom.”

NBA Sideline Reporter Craig Sager’s Message of Hope at LLS Blood Cancer Conference

A week after receiving the Jimmy V Perseverance ESPY Award, presented by Vice President Biden, where he delivered an emotional speech about his cancer battle, NBA Sideline Reporter Craig Sager again exhibited his #SagerStrong attitude as keynote speaker at The Leukemia & Lymphoma Society’s (LLS) Atlanta Blood Cancer Conference. Sager was diagnosed with acute myeloid leukemia (AML) in 2014. He announced this past march that his cancer is no longer in remission.

LLS “FACEBOOK LIVE” INSPIRES THE NEXT GENERATION OF SCIENTISTS

As schools and education communities across the country have had to adjust to a new way of learning online, The Leukemia & Lymphoma Society’s Pennies for Patients program (www.penniesforpatients.org), a science-based service-learning program for schools, has shifted in-person school learning events to a virtual semi-weekly STEM+ curriculum program to inspire the next generation of scientists and doctors.

Stock image of woman with hands on chest, breathing, in front of sunset

Exercise for blood cancer patients

Table of contents:​​

A phase 1 study of VIPER-101, a CD5-edited dual population chimeric antigen receptor cell therapy, to enhance immunotherapy against T-cell non-Hodgkin lymphoma

In October 2023, LLS made an equity investment in Vittoria to "Support Clinical Development of VIPER-101, a CAR-T Cell Therapy for T-cell lymphomas."

Genomics of Diffuse Large B Cell Lymphoma: pervasive role of super-enhancer hypermutation in dysregulating oncogene expression

We recently identified a pervasive, pathogenically relevant mutational mechanism that targets super-enhancers (SE) in DLBCL, leading to target gene deregulation. Here we will dissect the mechanistic role of 3 highly recurrent hotspots in the BCL6, BTG2 and CXCR4 SEs in driving lymphomagenesis and tumor dependency in vitro and in vivo using novel mouse models. These studies will significantly transform our understanding of DLBCL and identify novel therapeutic targets.